Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
You may also be interested in...
Cardio Catch-Up: Medtronic Plans To Buy Cathworks, Edwards Delays Evoque CE Mark, And More
Part II of highlights the cardiovascular tech sectors includes news from Medtronic, Edwards Lifesciences, and Abbott, plus a look at the upcoming TCT Conference in Boston.
Abbott Adds New Surgical Tissue Valves
The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.
Overflow Issue With Abbott COVID Tests Could Result In False Positives
The mixture in some faulty Abbott PCR tests could cause COVID-19 positive samples to flow into neighboring negative samples, resulting in false-positive results.